baber/WOPTO huggingface dataset:
Patent AU-2730188-A (AU)
Title: Fiber reinforced composites with improved glass transition temperatures
Inventor: JORDAN ROBERT CANFIELD
IPC: C07D303/24
Filed: 1988-12-20
Abstract: A fiber reinforced composite structure having a glass transition temperature greater than 150 DEG C is comprised of:     a) reinforcing fiber and   b) a curable epoxy resin composition comprising   (i) one or more epoxides having more than one epoxide group per molecule, of which epoxides at least 10 percent by weight is a 9,9-bis[4-(2,3-epoxypropoxy)phenyl]fluorene, all of the fluorene epoxy present being free of ortho substitution;   (ii) an effective amount of one or more epoxy curing agents.   n
Patent AU-2770495-A (AU)
Title: Complementary adenoviral vector systems and cell lines
Inventor: KOVESDI IMRE
IPC: C12N15/86
Filed: 1995-06-07
Abstract: The present invention provides multiply deficient adenoviral vectors and complementing cell lines. Also provided are recombinants of the multiply deficient adenoviral vectors and a therapeutic method, particularly relating to gene therapy, vaccination, and the like, involving the use of such recombinants. <IMAGE>
Patent AU-2802199-A (AU)
Title: Compositions and methods of treating tumors
Inventor: GREENE MARK I
IPC: A61K51/00
Filed: 1999-03-04
Abstract: Methods of treating an individual who has an  erb B protein mediated tumor is disclosed. Methods of preventing  erb B protein mediated tumors in an individual are disclosed. The methods comprise adminstering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an  erb B protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed.
Patent AU-2848501-A (AU)
Title: Integrity check in a communication system
Inventor: VIALEN JUKKA
IPC: H04L9/18
Filed: 2001-01-23
Abstract: A node is disclosed for use in a system comprising said node (6) and a further node (20). A plurality of different communication channels are provided between said nodes, each communication channel having a different identity. The node comprises means for calculating an authentication code (XMAC-I) from a plurality of values. Some of said values are the same for said plurality of different communication channels, while at least one of said values being arranged to comprise information relating to the identity of a communication channel (RB ID) of said plurality of communication channels. The node further comprises means for receiving information relating to an authentication code (MAC-I) calculated by said further node, and means for comparing information relating to an authentication code (XMAC-I) calculated by said node with information relating to an authentication code (MAC-I) calculated by the further node. <IMAGE>
Patent AU-2910599-A (AU)
Title: Detecting atherosclerosis in humans
Inventor: SHANKAR R
IPC: G06F19/00
Filed: 1999-05-18
Abstract: The present invention relates to a method for detecting the onset of atherosclerosis and for detecting the degree of atherosclerosis. Accordingly, one aspect of the present invention correlates data obtained from arteries having a measured amount of stenosis with actual arterial data (blood volume change vs. cuff pressure) obtained from a patient which is converted into data relating to the patient's arterial peak compliance. Another aspect of the present invention detects the onset and the degree of atherosclerosis by classifying the shape of a curve obtained by relating arterial blood volume change with cuff pressure. Two devices can be used, an electrical impedance plethysmograph and a volume plethysmograph.
Patent AU-2976095-A (AU)
Title: Use of selegilin in the treatment of epileptic conditions
Inventor: LOSCHER WOLFGANG
IPC: A61P25/08
Filed: 1995-07-27
Abstract: PCT No. PCT/DE95/00981 Sec. 371 Date Feb. 11, 1997 Sec. 102(e) Date Feb. 11, 1997 PCT Filed Jul. 27, 1995 PCT Pub. No. WO96/04897 PCT Pub. Date Feb. 22, 1996The invention relates to the use of selegiline (=L-N-(1-phenylisopropyl)-N-methyl-N-propynylamine) or pharmaceutically utilizable salts thereof in pharmaceuticals with an antiepileptic effect.
Patent AU-3117395-A (AU)
Title: Streptogramine derivatives, preparation of same and pharmaceutical compositions containing same
Inventor: BARRIERE JEAN-CLAUDE
IPC: A61P43/00
Filed: 1995-07-31
Abstract: PCT No. PCT/FR95/01025 Sec. 371 Date Jan. 31, 1997 Sec. 102(e) Date Jan. 31, 1997 PCT Filed Jul. 31, 1995 PCT Pub. No. WO96/04299 PCT Pub. Date Feb. 15, 1996Streptogramine derivatives of general formula (I) below, wherein the radical R1 is a methyl or ethyl radical, the radical R2 is a bromine or chlorine atom, or is an alkenyl radical with 3 to 5 carbon atoms when R3 and R4 are methyl, and one of R3 and R4 is a hydrogen atom or a methyl radical and the other is a methyl radical are disclosed. The streptogramine derivatives of general formula (I) have particularly useful antibacterial properties, and may be used in combination with a pristinamycin II derivative.   <IMAGE>
Patent AU-3151093-A (AU)
Title: Aromatic esters of phenylenedialkanoates as inhibitors of human neutrophil elastase
Inventor: OLEKSYSZYN JOZEF
IPC: A61P43/00
Filed: 1992-12-01
Abstract: Compounds of the formula    <IMAGE>  (I)   <IMAGE> (II)  or   <IMAGE> (III)  wherein: R1, R2, R3 and R4, which may be the same or different, are selected from the group consisting of hydrogen, alkyl of 1-6 carbons, cycloalkyl of 3 to 6 carbons, alkenyl of 2-6 carbons, or together represent methylene groups -(CH2)n-where n is a whole number from 1 to 6, provided that R1 and R2 or R3 and R4 are not both hydrogen; R5 and R6, which may be the same or different, are selected from the group consisting of hydrogen, halogen, nitro or -S(O)nR7 where n is 0, 1 or 2 and R7 is an optionally substituted alkyl of 1-12 carbons atoms; and both Ar substituents are optionally substituted heteroaromatic rings or one Ar is such heteroaromatic ring and the other is optionally substituted phenyl, the optional substitution for Ar being halogen, nitro or -S(O)nR7 where n and R7 have the value given above. The compounds are useful as inhibitors of human neutrophil elastase.
Patent AU-3176089-A (AU)
Title: Surgical instrument for establishing compression anastomosis
IPC: A61B17/11
Filed: 1989-03-28
Abstract: A surgical instrument (10) for installing a plurality of interlocking coupling members (42, 44, 46) forming a compression anastomosis assembly (40), particularly suitable for use in achieving anastomosis of a resected tubular organ. Disclosed and claimed is a dual locking feature for alternately locking a driving component and an aligning component against movement where, in a fist mode, the aligning component is operative when the driving component is locked and, in a second mode, the driving component is operative when the aligning component is locked. Additionally disclosed is a unique aligning component for aligning and exerting a compressive force on members of an associated coupling assembly.Optionally, the instrument has a cutting portion designed and configured for rotational movment as the cutter (80) advances to perform its intended functions of severing tissue and at least a portion of one of the members of the assembly. Lastly, there is disclosed a surgical instrument capable of assuming a variety of configurations to accommodate a number of anatomical orientations and operating situations.
Patent AU-3235795-A (AU)
Title: Computer process resource modelling method and apparatus
Inventor: HALEY MATTHEW A
IPC: G06F11/36
Filed: 1995-08-09
Abstract: An error detection mechanism for detecting programing errors in a computer program. A component of the computer program, e.g., a procedure or function of the computer program, is analyzed to determine the effect of the component on resources used by the computer program. A component is analyzed by traversing the computer instructions, i.e., statements, of the component and tracking the state of resources used by the component as affected by the statements of the component. Each resource has a prescribed behavior represented by a number of states and transition between states. Violations in the prescribed behavior of a resource resulting from an emulated execution of the statements of the component are detected and reported as programming errors. Resources used by two or more components are modelled by modelling externals of the components. The effect of execution of a component on externals and resources of the component is determined by traversing one or more possible control flow paths through the component and tracking the use of each external and resource by each statement of each control flow path. Once the effect of execution of a component on externals and resources of the component is determined, a model of the component is created and used to model externals and resources of other components which invoke the modelled component.
Patent AU-3311299-A (AU)
Title: Butorphanol sustained release formulations
Inventor: CHANG HUNG-CHIH
IPC: A61K47/44
Filed: 1999-02-25
Abstract: Controlled, sustained release formulations of butorphanol are provided. Such formulations can be an aqueous suspension of butorphanol freebase or an oil suspension of a butorphanol salt. Processes for using such formulations to provide long term analgesia are also provided.
Patent AU-3330184-A (AU)
Title: Immune interferon and method for its purification
Inventor: HONDA SUSUMU
IPC: C07K16/00
Filed: 1984-09-19
Abstract: An intact human immune interferon protein and a method for its extraction and purification is disclosed. This method permits the purification to homogeneity of intact recombinant human immune interferon using extraction of transformed microorganisms containing the interferon with a protease inhibitor, such as guanidine-HCl, and purification with monoclonal antibodies to immune interferon.
Patent AU-3729301-A (AU)
Title: Drive mechanism for a screw pump
Inventor: STEFFENS RALF
IPC: F04C29/00
Filed: 2001-01-12
Abstract: The invention concerns a screw pump (10) that is configured as a dual-shaft positive displacement motor and that comprises two positive displacement spindle rotors (1 and 2) rotating in opposite directions and having external toothing. In order to provide a quiet and simple drive mechanism for said rotors (1 and 2) while ensuring synchronization and increased rotational speed, contrate gear-like gearwheels (3 and 4) are mounted on both rotors (1 and 2) rotating in opposite directions or the rotor spindles in a corresponding plane, in which a larger contrate gear-like driving toothed wheel (5) engages in such a way that both spindle rotors (1 and 2) are driven in opposite directions at an increased rotational speed, wherein said contrate gear similarity also includes a crown gear with internal and external toothing working in connection with front toothed wheels or bevel gears and the possibility that only the driving toothed wheel (5) or only the driven gearwheels (3 and 4) are contrate gear-like.
Patent AU-3751195-A (AU)
Title: Foamed adhesives and method of application
Inventor: WARD DAVID
IPC: C09J5/08
Filed: 1995-10-31
Abstract: A process for applying a non-uniform coating of foamed adhesive to a substrate, wherein a quantity of foamed adhesive is initially applied to the substrate, characterized in that a plurality of grooves are generated in the foam. The adhesive may comprise an aqueous emulsion of a latex and foaming agent, the adhesive preferably comprising a mixture of an anionic and an amphoteric surfactant.
Patent AU-3793797-A (AU)
Title: Device user interface with topology map
Inventor: IWAMURA RYUICHI
IPC: G06F3/0482
Filed: 1997-06-20
Abstract: A topology map for a system is generated and displayed on a display device to indicate the various components which make up the system. The various components are indicated using icons each of which represent a respective one of the components. When a device is added to the system, a graphical image representing that device is automatically displayed in a graphical user interface. Similarly, when a device is removed from the serial bus, the graphical image representing that device is grayed out, leaving a shadow of the graphical image until the device is either re-coupled or the system is powered off. In a preferred embodiment, a user specifies a source device and a receive device by manipulating the corresponding icons so as to cause a data transfer between the source device and the receive device. In another embodiment, one or more task windows are included in the interface which help the user slect the task to be performed. Once selected, controls, commands and data related to the task are displayed within a control display window of the graphical user interface. Data transfer operations may include the transfer of video data, audio data, or both. In a further preferred embodiment, the digital network corresponds to the IEEE 1394 Serial Bus Standard.
Patent AU-3867393-A (AU)
Title: Mepiquat chloride
Inventor: HICKEY JOSEPH A
IPC: A01G7/00
Filed: 1993-05-19
Abstract: Solid mepiquat chloride sealed into a water-soluble pouch or into a water-soluble encapsulated solid form (e.g. granule, pellet, or briquette) for convenient handling. The pouch contains powdered mepiquat chloride or the encapsulated solid is merely introduced directly into a spray tank or reservoir for application with low human exposure and no containers in contact with the mepiquat chloride that require disposal. Mepiquat chloride can be used as a component of a system for growing a number of commodity plants including cotton.
Patent AU-3954389-A (AU)
Title: Dual source parenteral infusion system with secondary infusion module
Inventor: EGGERS PHILIP N
IPC: A61M5/14
Filed: 1989-08-11
Abstract: A dual source parenteral infusion system includes a primary controller (20) which controls the flow rate of a parenteral solution, a display (28) which displays parameters associated with the delivery of a primary solution (2), and pushbuttons (30) for entering solution delivery parameters into the controller (20). The primary controller (20) communicates with a secondary infusion module (40) which is programmed to deliver solution from a secondary source (24), with the flow rate being controlled by the primary controller (20). The secondary infusion module (40) includes a display (42) for displaying parameters associated with the delivery of the secondary solution (24) and a drop detector, and mounts about a drip chamber for the secondary solution (24). The module (40) may also include pushbuttons (44) for entering fluid delivery parameters for the secondary solution (24) into the module (40).
Patent AU-3974089-A (AU)
Title: Multi focal intra-ocular lens
Inventor: KALB IRVIN M
IPC: A61F2/16
Filed: 1989-07-11
Abstract: The invention comprises an IOL with at least a center zone and two concentrically located ring zones arranged thereabout, the center zone having a distance power correction. The first concentric ring zone has a near power correction and the second concentric zone a distance power correction. In one embodiment the lens body is provided with haptics which act to center the lens body when it is surgically implanted within the posterior lens capsule. In other embodiments, the lens diameter is increased to mate with the internal dimensions of the posterior lens capsule or is provided with an encircling haptic which bears against the posterior lens capsule.
Patent AU-4005089-A (AU)
Title: Solar protective filter
IPC: G02B5/20
Filed: 1989-08-18
Abstract: A filter, for protection against the sun, of improved contrast sensitivity has a spectral transmission (T lambda ) which for wavelengths ( lambda ) of the incident radiation in the range  lambda < 350 nm </=1% and in the range 350< lambda <400 nm is less than 20%, and which in the range 400< lambda <500 nm reaches a value of 5-30% and thereafter, proceeding from the value for T500, increases linearly with the wavelength to its maximum value. This progression is achieved by coating or colouring the filter material. In this case, it is advantageous to provide a component of the coating or colouring so that the spectral transmission (T lambda ) outside the visible spectral range, i.e. for values  lambda >780 nm, quickly reaches a value <1% again. <IMAGE>
Patent AU-4070085-A (AU)
Title: Production of tool steels using chemically prepared v2 o3 as a vanadium additive
Inventor: MOORE FAULRING GLORIA
IPC: C22C33/00
Filed: 1985-03-11
Abstract: Process for producing tool steel wherein a vandadium additive consisting essentially of chemically prepared, substantially pure V<sub>2</sub>O<sub>3</sub> is added to a molten steel having a carbon content above about 0.35 wt.% and containing silicon in an amount of from about 0.15 to about 3.0 wt.% and wherein a slag covering the molten steel contains CaO and SiO<sub>2</sub> in a weight ratio (CaO/SiO<sub>2</sub>) which is equal to or greater than unity.
Patent AU-4093099-A (AU)
Title: Method for pressure mediated selective delivery of therapeutic substances and cannula
Inventor: WIENER STEPHEN M
IPC: A61F2/958
Filed: 1999-05-21
Abstract: Methods and devices are disclosed for selective delivery of therapeutic substances to specific histologic or microanatomic areas of organs. Introduction of the therapeutic substance into a hollow organ space (such as an hepatobiliary duct or the gallbladder lumen) at a controlled pressure, volume or rate allows the substance to reach a predetermined cellular layer (such as the ephithelium or sub-epithelial space). The volume or flow rate of the substance can be controlled so that the intralumenal pressure reaches a predetermined threshold level beyond which subsequent subepithelial delivery of the substance occurs. Alternatively, a lower pressure is selected that does not exceed the threshold level, so that delivery occurs substantially only to the epithelial layer. Such site specific delivery of therapeutic agents permits localized delivery of substances (for example to the interstitial tissue of an organ) in concentrations that may otherwise produce systemic toxicity. Occlusion of venous or lymphatic drainage from the organ can also help prevent systemic administration of therapeutic substances, and increase selective delivery to superficial epithelial cellular layers. Delivery of genetic vectors can also be better targeted to cells where gene expression is desired. The access device comprises a cannula with a wall piercing tracar within the lumen. Two axially spaced inflatable balloons engage the wall securing the cannula and sealing the puncture site. A catheter equipped with an occlusion balloon is guided through the cannula to the location where the therapeutic substance is to be delivered.
Patent AU-4093597-A (AU)
Title: Use of bilayer forming emulsifiers in nutritional compositions comprising divalent metal salts
Inventor: MEHANSHO HAILE
IPC: A23L1/304
Filed: 1997-08-28
Abstract: Nutritional iron compositions comprising bioavailable sources of iron selected from ferrous fumarate and ferrous succinate where the iron source is preferably spread on the surface of a lecithin coated edible carrier such as sucrose. These nutritional iron compositions are particularly useful in food and beverage products such as chocolate flavored edible mixes, especially chocolate flavored beverages, that are additionally fortified with other minerals and vitamins, especially multi-mineral and vitamin combinations involving, iodine, vitamin A, vitamin C, riboflavin, and folic acid to avoid developing an undesirable color, off-flavor, astringency, particularly when the edible and/or beverage mix is reconstituted with water or milk.
Patent AU-4395000-A (AU)
Title: Medicament for treating diabetes
Inventor: SANDER SUNTJE
IPC: A61K38/46
Filed: 2000-03-15
Abstract: The use of physiologically acceptable enzyme mixtures having lipolytic, proteolytica and amylolytic activity, of microbial or animal origin, preferably digestive enzyme mixtures such as pancreatin or digestive enzyme mixtures containing pancreatin, for the treatment of diabetes. The invention also relates to the production of pharmaceutical compositions suitable for such treatment. A preferred variant of the invention relates to use of this enzyme mixture having lipolytic, proteolytic and amylolytic activity, especially digestive enzyme mixtures such as pancreatin or digestive enzyme mixtures containing pancreatin, for the adjuvant treatment of type I or type II diabetes mellitus.
Patent AU-4554985-A (AU)
Title: Improvements in or relating to interferons
Inventor: HAUPTMANN RUDOLF
IPC: C12N15/20
Filed: 1985-07-29
Abstract: The type I interferon peptides encoded by the genetic DNA sequences are called omega-interferons and are produced using appropriate expression vehicles and organisms.
Patent AU-4663789-A (AU)
Title: Amplified dna assay
Inventor: KEMP DAVID JAMES
IPC: C12N15/10
Filed: 1989-12-08
Abstract: A method for capturing amplified target DNA on a solid substrate comprising incorporating a ligand into said DNA by a polymerase chain reaction using a set of primers wherein one of the primers bears the ligand, and contacting the so treated DNA with a solid substrate having a binding reagent for said ligand immobilized thereon.
Patent AU-4782097-A (AU)
Title: Coagulating agent for liquid crystal solutions with base of cellulose substances
Inventor: MERALDI JEAN-PAUL
IPC: C08B1/00
Filed: 1997-10-15
Abstract: The invention concerns a coagulating agent for liquid crystal solutions with a base of cellulose substances, characterised in that it contains at least one water soluble additive selected from the group consisting of ammonia, amines of salt of these compounds, the additive being such that the pH of the said coagulating agent is greater than 6. A preferable additive is a salt elected from the group consisting of ammnonium formates, acetates and phosphates, mixed salts of these compounds, or mixtures of these constituents, in particular diammonium orthophosphates (NH4)2HPO4. The invention also concerns a method for spinning a liquid crystal solution with a base of cellulose substances, using a coagulating agent as per the invention, in particular the method called the "dry-jet-wet-spinning" as well as spun articles, fibers or films, obtained by these methods. The invention further concerns a cellulose fiber having toughness higher than 40 cN/tex, an initial modulus of elasticity higher than 1200 cN/tex and high fatigue strength: its breaking load degeneration DELTAF after 350 fatigue cycles in the so-called "specimen test", under a compression rate of 3.5% and a tensile stress of 0.25 cN/tex, is less than 30%.
Patent AU-4826493-A (AU)
Title: Anti-feline immunodeficiency virus (fiv) vaccines
Inventor: FRANCIS MICHAEL JAMES
IPC: C07K17/08
Filed: 1993-09-20
Abstract: The present invention provides a synthetic polypeptide comprising all or a portion of an amino acid sequence selected from (I), or an antigenic fragment, functionally-equivalent variant or pharmaceutically acceptable salt thereof. Also provided are nucleic acid molecules encoding such polypeptides, methods for their preparation, vaccine compositions containing them, and their use, both in combatting FIV and in diagnosing FIV infection.
Patent AU-4843897-A (AU)
Title: Converter for converting electrical energy
Inventor: TACHON OLIVIER
IPC: H02M7/44
Filed: 1997-12-17
Abstract: The converter has a source of potential (VE) and a source of current (SC). Each output is associated with a cell containing a capacitor (C). Control of the converter is performed by determining the error between the measured current in the current source and a reference current (Iref). In response, the current in all of the cells is modified. The current in each cell is controlled by control of switches in each cell to produce pulse modulated control of the current in each cell. The timing of the switching in each cell is offset from the switching in other cells to prevent transient surges.